news and press
featured news from sequence bio
NL Health Services selects Sequence Bio as an Innovation Partner
October 26, 2023
Sequence Bio research posters selected for presentation at ASHG 2023
November 1, 2023
Sequence Bio appoints Lynn Healey as Chief Executive Officer
September 5, 2023
Sequence Bio
drug target discovery powered by the founder effect
Accelerating the development of new medicines relies on discovering better drug targets.
Getting there means finding the biological components - or true signals - of disease. Sequence Bio was founded on the belief that Newfoundland and Labrador is the best place to look.
NEWFOUNDLAND AND LABRADOR
there's nowhere quite like it
Better target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes.
The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.
founder effect: less biological variation enables more efficient identification of low frequency, high impact variants
complete health records: highly consistent phenotypic stratification to uncover new links between variants and disease
RESEARCH & DEVELOPMENT
better medicines, faster
Our platform is where systems biology and data-driven computation meet to identify the true signals of disease.
See how we’re working with leading pharma and biotech to shorten R&D timelines with custom discovery cohorts.
newfoundland & labrador genome project
Sequence Bio’s NL Genome Project is researching the genetic makeup of 10,000 volunteering participants in Newfoundland and Labrador. By studying our province’s one-of-a-kind DNA and health information, we hope to discover better, safer medicines and improve how we treat and prevent diseases.
sequence bio
leadership
We’re a committed team local and global experts united in our mission to help improve health outcomes with better medicines, faster.
We're hiring, join the team
Lynn Healey
Chief Executive Officer
Joy Buckle MBA MSc
VP, Policy & Planning
Chris McDonald
VP, strategy & market development
Bari Ballew PhD
Senior Director, Data Science & Analytics
Alain O'Dea
Senior Director, Security and Infrastructure
Gerry Mugford PhD
Director, research
Diane Power
Director, Research Coordination
Blair Davis
Director, Medical Partnerships
Kendra Lane
Director, Human Resources
ADVISED BY THE BRIGHTEST MINDS
scientific advisory board
Dr. Euan Ashley
Stanford medicine
Dr. Pek Lum
auransa inc.
SEQUENCE BIO LEADERSHIP
board of directors
Mark Dobbin
killick capital
Brendan Paddick
columbus capital
John Phillips
klister credit corp
Sequence Bio is conducting research in Newfoundland and Labrador, and doing so in an ethical way is our first priority. Our research efforts require approval by the Health Research Ethics Board (HREB), and the words “believe,” “expect,” “anticipate,” and similar expressions, among others, generally identify our intent and/or objective to undertake additional research in this province.
Sequence Bio does not share information about planned research studies until they are approved.
JOIN OUR MAILING LIST
Stay up to date with Sequence Bio!
By signing up for our mailing list, you are consenting to receive emails from us regarding our services. You may unsubscribe at any time.